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The outcomes of the treatment of thrombotic thrombocytopenic purpura (TTP) have been shown to be improved by 
the administration of plasma exchange. However, treatment options are currently limited for cases refractory to plasma 
exchange.  The  autoantibodies  that  block  the  activity  of  ADAMTS13  have  been  demonstrated  to  play  a  role  in  the 
pathogenesis of TTP; therefore, high-dose immunoglobulin, which can neutralize these autoantibodies, may be useful for 
refractory  TTP.  However,  successful  treatment  with  high-dose  immunoglobulin  for  TTP  refractory  to  plasma  exchange 
and  corticosteroids  has  yet  to  be  reported  in  Korea.  Herein,  we  describe  a  refractory  case  which  was  treated 
successfully  with  high-dose  immunoglobulin.  A  29-year-old  male  diagnosed  with  TTP  failed  to  improve  after  plasma 
exchange coupled with additional high-dose corticosteroid therapy. As a salvage treatment, we initiated a 7-day regimen 
of  high-dose  immunoglobulin  (400  mg/kg)  infusions,  which  resulted  in  a  complete  remission,  lasting  up  to  the  last 
follow-up at 18 months. High-dose immunoglobulin may prove to be a useful treatment for patients refractory to plasma 
exchange;  it  may  also  facilitate  recovery  and  reduce  the  need  for  plasma  exchange. 
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INTRODUCTION
Thrombotic  thrombocytopenic  purpura  (TTP)  is  a  condition 
characterized  by  thrombocytopenia,  microangiopathic  hemolytic 
anemia,  and  less  frequently  with  neurological  deficits,  renal 
failure, and fever. TTP is a rare disease, and has been reported 
to affect only 3.7 persons per one million annually in the United 
States
1). It frequently follows a fatal course; 95% of patients die 
within three months if not treated
2). TTP pathogenesis has been 
associated  with  deficiencies  in  the  metalloproteinase,  ADAMTS13 
(A Desintegrin And Metalloprotease with a ThromboSpondin like 
domain  13)
3).  The  principal  function  of  ADAMTS13  involves  the 
cleavage  of  unusually  large  forms  of  von  Willebrand  factor 
(ULVWF),  thereby  preventing  ULVWF  multimers  from  accumula-
ting  in  the  circulation;  platelet  aggregation  in  TTP  is  thought t o  
be the consequence of the binding of the platelets from ULVWF 
remaining  in  the  circulation
4, 5).  Immunoglobulin  G  (IgG) 
autoantibodies  that  block  the  activity  of  ADAMTS13  have  been 
detected in patients suffering from TTP; this may account for the 
impairment of ADMATS13 characteristically observed in cases of 
TTP
6, 7). 
Plasma exchange was introduced in the 1980s as a treatment 
for  TTP,  and  is  currently  the  treatment  of  choice  for  the 
condition
2). The principal mechanism of action relevant to plasma The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  3,  September  2008 162
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Figure  1. S D S - a g a r o s e  g e l  e l e c t r o p h o r e s i s  w i t h  n o r m a l  h u m a n  p l a s m a  
calibration shows severe deficiency, less than 5%, of ADAMTS13 in the 
patient  sample.  The  multiple  observed  represent  the  von  Willebrand 
factor-multimer,  which is  not  degraded  due to  the  lack  of  ADMATS13. 
Thus,  multiple  bands  on  SDS-agarose  gel  electrophoresis  indicate  a 
lack of ADMATS13 activity. On the X-axis, the number 100 designates 
the  intact  activity  of  ADAMTS13,  i.  e.  100%  activity  of  ADAMTS13 
results in an absence of multiple bands. However, the patient's sample 
shows  multiple  bands,  indicating  decreased  ADMATS13  activity.  N: 
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Figure  2. Serial changes of platelet counts, hemoglobin, and serum LDH.  Plasma  exchange  alone  failed to  improve  the hematological parameters;
the  addition  of  high-dose  methylprednisolone  did  not  result  in  improvement.  However,  improvement  in  all  hematological  parameters was  observed
following  the  administration  of  high-dose  immunoglobulin.
exchange  in  this  context  is  the  removal  of  IgG  autoantibodies 
and  accumulating  ULVWF,  in  addition  to  the  replacement  of 
ADMATS13.  Although  the  response  rate  to  plasma  exchange 
has been reported to be as high as 80%, patients refractory to 
plasma  exchange  have  also  been  reported
2, 8, 9).  In  plasma 
exchange-resistant  cases,  high-dose  corticosteroid  infusions  are 
often  employed  as  a  complement  to  continuing  plasma 
exchange
10).  However,  it  remains  unclear  as  to  how  to  treat 
patients who are refractory to both plasma exchange and steroid 
therapy. High dose immunoglobulin infusions have been reported 
to  induce  complete  remission  in  these  refractory  cases
9, 11, 12). 
However,  successful  treatment  via  immunoglobulin  infusions  in 
cases  refractory  to  both  plasma  exchange  and  steroid  therapy 
has  not  previously  been  reported  in  Korea.  In  this  report,  we 
describe a case refractory to both plasma exchange and steroid 
treatment  in  which  complete  remission  was  achieved  as  the 
result  of  a  high-dose  immunoglobulin  regimen. 
CASE REPORT 
A  29-year-old  male  presented  with  disturbed  mentality; 
aphasia  had  developed  one  day  prior  to  presentation.  The 
patient had a history of frequent epistaxis over the previous two 
weeks.  The  patient  was  otherwise  healthy,  with  an  unremark-
able  medical  history.  Upon  physical  examination,  the  conjunc-
tivas were anemic, and multiple petechiae were detected on the 
patient's trunk. The results of the admission blood tests were as 
f o l l o w s :  h e m o g l o b i n  ( H b )  7 . 1  g / d L ,  w h i t e  b l o o d  c e l l s  ( W B C )  
5,540/uL,  platelet  (PLT)  counts  4,000/uL,  reticulocytes  18.9%, 
and serum LDH 1,655 IU/L. The brain MRI revealed no abnormal 
findings,  such  as  hemorrhaging  or  inflammation;  an  18-channel 
EEG  revealed  moderate  to  severe  cerebral  dysfunction.  A  mild 
fatty liver and splenomegaly were noted on abdominal US. The 
peripheral  blood  smear  evidenced  normocytic  normochromic 
anemia  and  severe  thrombocytopenia;  these  findings  were 
compatible  with  microangiopathic  hemolysis  including 
schistocytosis.  The  results  of  both  direct  and  indirect  Coombs' 
tests  were  negative.  SDS-agarose  gel  electrophoresis  for 
ADAMTS 13 indicated that the ADAMTS 13 activity was as low 
as  0.89%  (Reference  value:  50～150%,  Figure  1). 
The  patient  was  diagnosed  with  TTP,  and  plasma  exchange 
was immediately initiated. However, after 14 days of daily plasma 
exchange  treatments  with  fresh  frozen  plasma  or 
cryoprecipitate-depleted plasma, the patient's hematological and 
cognitive abnormalities remained unimproved: Hb 7.3 g/uL, WBC 
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4,500/uL, PLT 5,000/uL, and serum LDH 1,665 IU/L. Therefore, 
the  patient  was  started  on  a  regimen  of  high-dose  methyl-
p r e d n i s o l o n e  ( 2  m g / k g )  t w i c e  d a i l y  o n  D a y  1 0 ,  a s  a  compl ement 
to continuing plasma exchange. High-dose steroids were infused 
intravenously  after  plasma  exchange  each  day.  However,  the 
patient  did  not  respond  to  this  treatment,  and  the  disturbed 
mentality  and  thrombocytopenia  persisted.  We  then  initiated 
intravenous  infusions  of  high  dose  human  immunoglobulin  (400 
mg/kg)  on  Day  21.  After  commencing  the  human  immune 
globulin  infusions,  the  patient's  mentality  began  to  show 
improvements,  and  the  number  of  PLT  increased  gradually,  up 
to  100,000/uL  (Figure  2).  At  that  point,  we  discontinued  the 
plasma  exchange  regimen.  The  patient's  cognitive  abilities 
recovered  completely,  and  the  follow-up  EEG  evidenced  no 
abnormal  findings.  The  patient's  hematological  findings  were 
n o r m a l i z e d  a s  f o l l o w s :  H b  1 3 . 5  g / u L ,  P L T  2 3 4 , 0 0 0 / u L ,  s e r u m  
LDH 355 IU/L. The patient remains well after 18 months follow- 
up,  with  no  signs  of  relapse.
DISCUSSION
Since  the  introduction  of  plasma  exchange  as  a  treatment, 
the  mean  number  of  plasma  exchanges  required  to  induce 
c o m p l e t e  r e m i s s i o n  f o r  T T P  h a s  b e e n  r e p o r t e d  t o  b e  7  t o  1 6  
exchanges
13). An initial response is normally observed within the 
first  three  days  of  treatment
10).  However,  10  to  20  percent  of 
patients  evidence  a  transient,  incomplete,  or  no  response  to 
plasma  exchange;  it  is  not  currently  possible  to  identify  poor 
responders prior to treatment. Thus far, no treatment strategy for 
TTP  refractory  to  plasma  exchange  has  been  established.  In 
cases  of  poor  response  or  resistance  to  plasma  exchange, 
several  treatment  modalities  have  been  recommended. 
First,  the  frequency  of  plasma  exchange  can  be  increased 
from  once  daily  to  twice  daily;  twice-daily  exchanges  of  one 
volume of plasma have been demonstrated to constitute a more 
effective  replacement  therapy  than  increasing  the  volume  of  a 
single  daily  exchange
14).  However,  the  economics  inherent  to 
such an approach must be considered, as only a limited number 
of plasma exchanges are covered by Korean medical insurance. 
Second, the cryosupernatant fraction of the plasma (also known 
as the cryoprecipitate-depleted plasma) can be employed, rather 
than fresh frozen plasma; the efficacy of plasma exchange may 
be  attenuated  by  VWF  multimers  which  normally  remain  in  the 
fresh  frozen  plasma.  Cryoprecipitate-  depleted  plasma  tends  to 
contain a very low level of VWF, because cryoprecipitate is quite 
rich  in  VWF
15, 16).  H o w e v e r ,  a  r a n d o m i z e d ,  c o n t r o l l e d  t r i a l  
identified  no  difference  in  efficacy  between  whole  plasma  and 
cryoprecipitate-poor plasma
17). In our case, we attempted to use 
cryoprecipitate-depleted  plasma,  but  effected  no  improvements 
in  either  the  neurological  or  hematological  manifestations. 
Third,  additional  immunosuppressive  treatments  have  been 
shown to elicit successful responses in cases of refractory TTP. 
These  treatments  utilize  high-dose  steroids  or  other  immuno-
suppressive agents, including cyclophosphamide, vincristine, and 
cyclosporine.  However,  there  is  currently  no  data  from  clinical 
trials  to  corroborate  the  efficacy  of  such  treatments
14).  In  the 
case  described  herein,  we  applied  high-dose  steroids  with 
intravenous infusions of methylprednisolone (125 mg) twice daily 
while  continuing  plasma  exchanges.  However,  this  treatment 
failed to improve the patient's condition. Recently, the anti-CD20 
monoclonal  antibody,  rituximab,  has  been  reported  to  induce 
complete  remission  in  cases  of  TTP  refractory  to  plasma 
exchange
18, 19). Weekly infusions of rituximab (375 mg/m
2) proved 
effective  in  the  control  of  the  neurological  and  hematological 
manifestations,  ostensibly  as  the  result  of  the  depletion  of 
B-lymphocytes,  which  were  generating  the  IgG  autoantibodies. 
These  findings  support  notion  that  IgG  autoantibodies  against 
ADAMTS13  are  important  in  the  management  of  TTP.  In 
addition,  a  previous  report  suggested  that  high  titers  of  IgG 
autoantibodies  might  be  associated  with  resistance  to  plasma 
exchange  in  TTP  patients
8). 
Another  possible  treatment  approach  is  high-dose  immuno-
globulin  infusions.  The  rationale  for  the  use  of  immunoglobulin i s  
based  on  the  fact  that  immunoglobulin  is  capable  of  neutralizing 
IgG autoantibodies against ADAMTS13
20). Although a retrospective 
study has reported that the application of immunoglobulin had no 
additional  benefits
21),  many  case  series  reports  have  noted  the 
efficacy of immunoglobulin in the management of TTP refractory to 
plasma  exchange
9, 11, 12).  Our  experience  supports  the  use  of 
high-dose  immunoglobulin  infusion  as  an  effective  salvage 
treatment  for  cases  of  TTP  refractory  to  plasma  exchange. 
Plasma  exchange  should  continue  to  be  the  first-line  treat-
ment  for  patients  diagnosed  with  TTP.  However,  appropriate 
salvage  treatment  should  be  considered  without  delay  in  cases 
refractory  to  both  repeated  plasma  exchange  and  high-dose 
steroid  therapy.  High-dose  immunoglobulin  infusions  may 
represent a useful treatment option for these refractory cases. In 
addition,  this  treatment  may  facilitate  recovery  and  reduce  the 
plasma  exchange  requirements.  However,  further  study  is 
warranted  to  determine  the  optimal  treatment  protocols  for 
high-dose  immunoglobulin  therapy. 
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